Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02956460 · ClinicalTrials.gov registry record · NA

Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses

A NA study of Myopia, sponsored by CooperVision.

Completed
Registry status
NA
Development phase
64
Enrollment target
4
Study locations

NCT02956460: Completed NA study of Myopia, sponsored by CooperVision.

NCT02956460 is a NA study of Myopia that has completed, run by CooperVision. The registered enrollment target is 64 participants, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02956460, a NA study of Myopia, has completed, sponsored by CooperVision.

COMPLETED
Registry status
NA
Development phase
64 participants
Enrollment target
4
Study locations

Study Summary

Prospective, multi-center, bilateral, double-masked, randomized, cross-over, daily wear, 1 month dispensing study (2 weeks each lens pair)

Primary Outcome

Subjective assessment for comfort is assessed. Scale 0-10, 0=painful, 10=can't feel

Conditions Studied

Interventions

  • DEVICE senofilcon A
  • DEVICE fanfilcon A

Study Locations (4)

California

  • Eric M. White O. D., Inc - San Diego

Florida

  • Golden Vision - Sarasota

Kansas

  • Kannarr Eye Care - Pittsburg

Pennsylvania

  • Nittany Eye Associates - State College

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2016-10-27
Est. Completion 2016-12-14
Phase NA
CooperVision

64 total trials

What the finished NCT02956460 record still lists

NCT02956460 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 267-participant average among 90 other Myopia trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which senofilcon A is the first listed.

NCT02956460 reports a single indexed study location in California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT02956460 about?

NCT02956460 is a clinical study titled "Performance Comparison Between Fanfilcon A and Senofilcon A Sphere Lenses". Prospective, multi-center, bilateral, double-masked, randomized, cross-over, daily wear, 1 month dispensing study (2 weeks each lens pair)

What is the current status of trial NCT02956460?

This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2016-10-27. Estimated completion is 2016-12-14.

What conditions does trial NCT02956460 study?

This clinical trial studies the following conditions: Myopia.

What interventions are being tested in trial NCT02956460?

The interventions under investigation include: senofilcon A (DEVICE), fanfilcon A (DEVICE).

Who is sponsoring clinical trial NCT02956460?

This trial is sponsored by CooperVision, which has 64 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02956460 being conducted?

This trial has 4 study locations across California, Florida, Kansas, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Myopia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02956460's enrollment target sits among peer trials

64 57th of 90 higher than 34 of 90 other Myopia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01853631 · 64 participants · Phase 1

    Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)

  • NCT03739502 · 64 participants · Phase 2

    A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

  • NCT03739814 · 64 participants · Phase 2

    Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

  • NCT03866408 · 64 participants · Early Phase 1

    Insulin Regulation of Lipolysis and Lipolysis Proteins

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02956460, the US trial registry maintained by the National Library of Medicine. NCT02956460 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.